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Introduction
Trastuzumab is often featured as a prototype for future cancer
treatments. It is a rationally designed biologic agent that targets
the intracellular and extracellular domains of human epidermal
growth factor receptor 2 (HER2). The safety and efﬁcacy of
trastuzumab were ﬁrst demonstrated in patients with metastatic
breast cancer as monotherapy [1,2] or in combination with che-
motherapy [3–5]. More recently, trastuzumab has demonstrated
efﬁcacy as adjuvant therapy after surgery in patients with HER2-
positive early breast cancer. For this indication, at a cost of
$50,000 for 1 year of treatment, expenditures will approach an
expected $1 billion in the United States alone [6]. Thus, any
economic evaluation of the use of trastuzumab in adjuvant set-
tings deserves careful scrutiny.
In this issue of Value in Health, Skedgel et al. [7] report a
cost-effectiveness analysis of sequential adjuvant trastuzumab
using updated 2-year results from the Herceptin Adjuvant
(HERA) trial, a multinational study of 5102 women with HER2-
positive early breast cancer. After a median of 1 year of follow-
up, patients who received trastuzumab had signiﬁcantly greater
disease-free survival compared with patients who did not receive
trastuzumab (hazard ratio [HR], 0.54; 95% conﬁdence interval
[CI] 0.43–0.67) [8]. After 2 years of follow-up, Smith et al. [9]
found that the HR for disease-free survival was 0.64 (95% CI
0.54–0.76) and the HR for overall survival was 0.66 (95% CI
0.47–0.91).
One year of sequential trastuzumab therapy costs approxi-
mately Canadian $50,000. Assuming that the efﬁcacy of tras-
tuzumab extends to 5 years, Skedgel et al. estimated the
incremental cost-effectiveness ratio (ICER) to be $70,292 (95%
CI $28,606–$139,657) per quality-adjusted life-year (QALY).
The ICER increased to $127,862 per QALY when they assumed
the duration of beneﬁt was 3 years.
These results are a departure from the conclusions of several
previous cost-effectiveness analyses conducted using the 1-year
results from the HERA trial and from other trials of adjuvant
trastuzumab administered alongside standard chemotherapy (see
Table 1) [10–21]. Given that Skedgel et al. report ICERs exceed-
ing the often-cited thresholds of $50,000 and $100,000 per
QALY, the results are unlikely to go unnoticed by decision-
makers. Therefore, a close examination of the study assumptions
and methodological issues is warranted. Based on ﬁndings from
previous studies, the parameters that are most likely to inﬂuence
the results include (1) the cost of the treatment, (2) the duration
of the beneﬁt, and (3) the magnitude of the beneﬁt.
Cost of Treatment
Skedgel et al. applied a treatment cost of Canadian $51,693 (US
$42,721 [22]). This approach is consistent with most previous
studies evaluating 1-year treatment regimens, in which costs have
been approximately $40,000 to $50,000 with an additional
$5000 to $15,000 for administration and monitoring. Therefore,
the cost of treatment applied in this analysis does not account for
the higher ICER relative to previous studies.
Duration of Beneﬁt
Most outcomes researchers and economic analysts have assumed
that the risk of breast cancer recurrence is highest in the ﬁrst
few years after primary treatment and diminishes to zero after
approximately 20 years. Analysts have assumed varying periods
during which trastuzumab suppresses the risk of recurrence.
These assumptions are necessary, because the estimated impact of
the therapy is based on short-term studies and the true impact is
uncertain [23]. Most analysts have assumed that the beneﬁts of
trastuzumab continue for 5 years (see Table 1).
Like Skedgel et al., other analysts have found that beneﬁts
lasting less than 3 or 4 years can affect the ICER for trastuzumab.
For example, when Kurian et al. [11] assumed no beneﬁt after
year 4, the ICER exceeded $100,000 per QALY.
Because many previous cost-effectiveness analyses were based
on 1-year results from the HERA trial, analysts have noted that
their assumptions about the duration of beneﬁt of trastuzumab
would require validation from extended follow-up. With
extended follow-up, the data could support or discredit previ-
ously applied assumptions. However, 2 years of follow-up
in the adjuvant setting is still insufﬁcient to evaluate whether
an assumption of 3, 5, 10, or more years of beneﬁt is most
appropriate.
Skedgel et al. argue that the updated ﬁndings from the HERA
trial “suggest the statistically signiﬁcant duration of beneﬁt may
be less than ﬁve years.” The hazard rates reported by Smith et al.
[9] appear to support this statement. As shown in a ﬁgure by Smith
et al. [9], the hazard rates for the trastuzumab group and the
observation group varied during 3 years of follow-up; the relative
beneﬁt of trastuzumab appeared to diminish after 12 months to
18 months. However, the primary difﬁculty in interpreting these
data is that patients who initially were assigned to the observation
group were allowed to cross over to trastuzumab once the interim
results were reported. By May 2006, 861 of 1698 patients
(50.7%) in the observation group had crossed over to trastu-
zumab [9]. Skedgel et al. correctly point out that this could
“potentially bias the updated HERA results.” Although the
median duration since crossing over to trastuzumab was 2.6
months, others have reported that just 9 weeks of trastuzumab
may be sufﬁcient time for patients to beneﬁt from treatment [20].
Thus, the assumed lack of durable treatment beneﬁt as reported by
Smith et al. (and applied by Skedgel et al.) would have to rely
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on the assumption that delayed initiation of trastuzumab (in
patients who crossed over to trastuzumab) has no beneﬁt or risk.
This is unlikely, given the demonstrated efﬁcacy of trastuzumab in
later stages of disease [1–5] and the ﬁnding that relatively brief
courses of therapy provide clinical beneﬁt [18].
Magnitude of Beneﬁt
Most analysts evaluating the cost-effectiveness of adjuvant tras-
tuzumab have used the HR as the measure of treatment effect
(although they have sometimes referred to it as the relative risk).
In the ﬁve trials evaluating adjuvant trastuzumab, the estimated
HRs for disease-free survival ranged from 0.42 to 0.54
[8,9,18,20].
To address the potential bias associated with patients crossing
over to trastuzumab, Smith et al. [9] reported HRs using both an
intention-to-treat analysis and an analysis in which all patients
who crossed over to trastuzumab were censored on the date of
treatment initiation. The HR from the intention-to-treat analysis
was 0.64 (95% CI 0.54–0.76), and the HR from the censored
analysis was 0.63 (95% CI 0.53–0.75). The advantages of using
survival analysis include its capacity to allow for censoring of
patients who switched to trastuzumab and to account for varying
duration of follow-up (0–48 months).
Instead of applying this estimated HR, Skedgel et al. calcu-
lated a relative risk of 0.75 at 3 years. Estimation of relative risk
does not have the methodological advantages of the survival-
analytic methods discussed above, because it inherently assumes
that patients were at risk for 3 years. According to Smith et al.
[9], only 140 of 1703 patients (8.2%) assigned to trastuzumab
and only 127 of 1698 patients (7.5%) assigned to observation
were still at risk at 3 years. Skedgel et al. take the position that
the relative risk is more appropriate than the HR because the
HR “does not specify how the risk of an event changes over
time.” However, neither does the relative risk. The authors
further argue that the relative risk is more appropriate for ap-
plication to a “model [that] speciﬁcally incorporated time-
dependent rates of recurrence and mortality.” However, the
model appears to have used a constant rate of recurrence equal
to 0.09 events per year in years 1 through 5. Thus, there is an
inconsistency between the stated rationale for using relative
risks instead of HRs and how the measure of beneﬁt was used
in the model.
The authors further argue that the similarity of the HRs from
the intention-to-treat analysis and the censored analysis provides
evidence that crossover did not affect their estimate of treatment
beneﬁt. We do not agree. In an intention-to-treat analysis, beneﬁt
from delayed treatment with trastuzumab among patients in the
observation group will cause the relative beneﬁt of trastuzumab
to be underestimated. Thus, the true HR for recurrence or death
is likely to be less than 0.64, and certainly less than 0.75. In a
censored analysis, patients who cross over to trastuzumab are no
longer considered to be at risk for disease progression upon the
date of switching. If patients who crossed over to trastuzumab
had a higher inherent risk of recurrence, those who remained in
the observation group would show lower rates of recurrence and
the censored analysis would show a lower magnitude of beneﬁt
with trastuzumab (and vice versa).
Table 1 Economic evaluations of trastuzumab for early breast cancer
Study and country Source of efﬁcacy data
Measure of
treatment effect Duration of beneﬁt ICER
NICE, United Kingdom [17] HERA trial at 1 year HR: 0.54 5 years £18,000 per QALY
Millar and Millward,Australia [13] HERA trial at 1 year
and NCCTG N9831§
HR: 0.48*,† 5 years, diminishing
effect in years
6 through 8
AUS $22,793 per QALY
Dedes et al., Switzerland [15] HERA trial at 1 year HR: 0.54 5 years €19,673 per life-year gained (HERA)
Neyt et al., Belgium [14] HERA trial at 1 year HR: 0.54 Lifetime (assumed) €34,999 per life-year gained (stage I)
€16,026 per life-year gained (stage II)
€5,994 per life-year gained (stage III)
Liberato et al., Italy [10] HERA trial at 1 year‡ HR: 0.54 5 years €11,228 and $16,199 per QALY
Norum et al., Norway [16] HERA trial at 1 year, NSABP
B-31, and NCCTG N9831§
10% and 20% gain
in overall survival
20 years €19,176 per QALY with 20% gain
€44,934 per QALY with 10% gain
Liberato et al., Italy [10] NSABP B-31 and NCCTG N9831§ HR: 0.48† 5 years €14,861 and $18,970 per QALY
Kurian et al., United States [11] NSABP B-31 and NCCTG N9831§ Not reported 2 years, diminishing
effect in years
3 through 10
US $39,982 per QALY
Garrison et al., United States [12] NSABP B-31 and NCCTG N9831§ Not reported 5 years US $34,201 per QALY
Skedgel et al., Canada [7] HERA trial at 2 years RR: 0.754 5 years and 3 years Can $70,292 per QALY with 5-year
beneﬁt
Can $127,862 per QALY with 3-year
beneﬁt
Lidgren et al., Sweden [29] HERA trial at 2 years HR: 0.64 Lifetime €36,000 per QALY (lifetime beneﬁt)
€66,800 per QALY (5-year beneﬁt)
Shiroiwa et al., Japan [30] HERA trial at 2 years HR: 0.64 5 years ¥2,600,000, €17,000 per life-year gained
Dedes et al., Switzerland [15] FinHer study|| HR: 0.42 5 years Cost saving
Neyt et al., Belgium [14] FinHer study|| HR: 0.42 Lifetime (assumed) €668 per life-year gained (stage I)
Cost saving (stage II)
Cost saving (stage III)
*Termed relative risk, but corresponds to HR reported by Romond et al. [18] for combined analyses of NSABP B-31 and NCCTG N9831.
†Represents average of HRs for distant metastases reported by Romond et al. [18] for combined analyses of NSABP B-31 and NCCTG N9831 (0.47), and Piccart-Gebhart et al. [8] for the
HERA trial at 1 year (0.49).
‡Liberato et al. [10] performed a “HERA-like” analysis in which the model based on the NSABP B-31 and NCCTG N9831 trials was maintained and the HR of relapse from the HERA trial
(0.54) was applied, and the risk of cardiac toxicity and proportion of patients experiencing symptomatic cardiotoxicity were reduced.
§Median follow-up in NSABP B-31 and NCCTG N9831 was 2 years.
||Median follow-up in the FinHer study was 3 years.
FinHer, Finland Herceptin; HERA,HerceptinAdjuvant; HR, hazard ratio; ICER, incremental cost-effectiveness ratio;NCCTG,North Central CancerTreatment Group;NICE,National Institute
for Health and Clinical Excellence; NSABP, National Surgical Adjuvant Breast and Bowel Project; RR, relative risk; QALY, quality-adjusted life-year.
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When there is controversy about the assumptions used in a
pharmacoeconomic evaluation, analysts often conduct sensitivity
analyses to demonstrate the effects of alternative model inputs
and assumptions. Although Skedgel et al. did not explicitly apply
the measure of effect afforded by the HR, their threshold analyses
reveal that a relative risk less than 0.70 would result in an ICER
of less than $50,000 per QALY with a 5-year beneﬁt, a ﬁnding
that is more consistent with the results of previous studies.
Implications for Decision-Makers
The widely published technology assessments of the UK National
Institute for Health and Clinical Excellence (NICE) are relevant
for many budget-conscious health-care systems. NICE recom-
mends 1 year of treatment with trastuzumab for early-stage
HER2-positive breast cancer after chemotherapy with anthracy-
clines with or without taxanes [24]. The ﬁndings of the accom-
panying technology assessment, based on the 1-year results of the
HERA trial, are similar to those of other published economic
evaluations, showing a cost-effectiveness ratio of £18,500 per
QALY gained. In an editorial accompanying the 2-year results of
the HERA trial, Hind et al. (who were involved in the NICE
assessment) conjectured that the updated results may increase the
ICER above the NICE threshold of £20,000 per QALY [25].
However, they also note that substantial crossover in the trial
disallows an adequate assessment of whether trastuzumab pre-
vents or delays recurrence.
So, are the updated results from the HERA trial and the new
cost-effectiveness ratios persuasive enough to warrant NICE
or other decision-makers to reevaluate the cost-effectiveness of
trastuzumab?
Given the methodological concerns we have discussed and the
clinical issues yet to be resolved (e.g., sequential vs. concurrent
trastuzumab, duration of therapy), we think not. Nevertheless,
the analysis by Skedgel et al. highlights the critical importance of
retesting assumptions applied in cost-effectiveness analyses based
on early clinical ﬁndings. Fortunately, several trials have been
initiated in an attempt to determine the optimal duration of
therapy with trastuzumab [26–28]. If these trials demonstrate
that a shorter duration of therapy provides similar beneﬁts (and
perhaps less toxicity) than 1-year regimens, the reduction in the
cost of the therapy will increase the cost-effectiveness of adjuvant
trastuzumab.
On the other hand, there is a strong possibility that the
evidence will push costs in the opposite direction. If results from
the third arm in the HERA trial, the 2-year regimen, demonstrate
incremental beneﬁts over the 1-year regimen, a new round of
economic analyses will be warranted. Furthermore, numerous
trials are underway to evaluate the efﬁcacy of trastuzumab in
combination with other high-cost biologics compared with tras-
tuzumab alone. These studies will raise new questions.
Conclusion
With the increasing public attention on comparative effective-
ness, the transparency of economic evaluations will be essential if
the results are to assist policymakers and the public. It is not clear
how these audiences will respond to differences in methodologi-
cal approaches when those differences substantially affect the
results of a study. Periodic reviews could help to clarify important
methodological issues in analyses of speciﬁc technologies. Finally,
we must ensure that methods are robust, presentations are trans-
parent, and sensitivity analyses are expansive, if we are to be a
credible source of information for the hard choices that exist in
health care.
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